Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.
Xenia Androni, Rachel J. Boyd, Paul B. Rosenberg, Vasiliki Mahairaki
Front Dement August 4, 2025 DOI: 10.3389/frdem.2025.1605051 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Psychedelics psychedelic compounds Psychedelic exposure New therapies Alzheimer's Brain tissue Complete protein profile Proteins |
| Citations | 4 |
| Key findings | Psychedelic compounds induce neuroplastogenic and anti-inflammatory alterations that may be therapeutically useful for Alzheimer's disease. |
Abstract
Alzheimer's disease (AD) is characterized by a long preclinical phase lasting more than a decade before the onset of its clinical phase of mild cognitive impairment (MCI) or dementia. Recent advances in psychedelic research underscore numerous neuroplastogenic and anti-inflammatory alterations induced by these compounds, making them promising therapeutic candidates for AD. In this mini review, we will briefly summarize the existing literature using human cerebral organoids to study the molecular and metabolic changes caused by various psychedelic compounds, focusing on their potential therapeutic applications for AD.
Citations in the library
Cites 32
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports October 13, 2017
- Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo Neuron July 5, 2021
and 27 more in the library